CLV
Clinuvel Pharmaceuticals ADR
Stock
Stock
Ticker: CLVLY
CLVLY
Price
Price
CHART BY
Historical dividends and forecast
The next dividend will be paid on 28.09.2026
$0.0286
CHART BY
Frequently asked questions
What is Clinuvel Pharmaceuticals ADR's market capitalization?
The market capitalization of Clinuvel Pharmaceuticals ADR is 291.47M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Clinuvel Pharmaceuticals ADR's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Clinuvel Pharmaceuticals ADR is 12.58. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Clinuvel Pharmaceuticals ADR?
Clinuvel Pharmaceuticals ADR's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.464. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Clinuvel Pharmaceuticals ADR's stock?
Currently, 6 analysts cover Clinuvel Pharmaceuticals ADR's stock, with a consensus target price of 12.46. Analyst ratings provide insights into the stock's expected performance.
What is Clinuvel Pharmaceuticals ADR's revenue over the trailing twelve months?
Over the trailing twelve months, Clinuvel Pharmaceuticals ADR reported a revenue of 64.31M.
Is Clinuvel Pharmaceuticals ADR paying dividends?
Yes, Clinuvel Pharmaceuticals ADR is paying dividends. The next payment is scheduled for 28.09.2026, with an expected amount of .
What is the EBITDA for Clinuvel Pharmaceuticals ADR?
Clinuvel Pharmaceuticals ADR's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is 28.63M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Clinuvel Pharmaceuticals ADR?
Clinuvel Pharmaceuticals ADR has a free cash flow of 24.81M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Financials
- Market Cap
- 291.47M
- EPS (TTM)
- $0.464
- P/E ratio (TTM)
- 12.58
- Revenue (TTM)
- 64.31M
- EBITDA (TTM)
- 28.63M
- Free Cashflow (TTM)
- 24.81M
Pricing
- 1D span
- $5.546$5.875
- 52W span
- $5.60$8.12
Analyst Ratings
The price target is 12.46 and the stock is covered by 6 analysts.
Buy
3
Hold
3
Sell
0
Information
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- CLVLY
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet